Thrombotic thrombocytopenic purpura (TTP)
Board exam relevance: in 4 of more than 100 exam reports · rank 90- Synonyms
- Moschcowitz syndrome, thrombotic microangiopathy, ADAMTS13 deficiency, Upshaw-Schulman syndrome, iTTP
- Specialty
- Internal medicine · Haematology & oncology
- Images
- Blood smear & cytology 2
- Last updated
- 10/2026 · Dr. Pascal Bafteh
Contents
Images (2)
Blood smear & cytology
Blood smear & cytologyDefinition
Thrombotic thrombocytopenic purpura (TTP, Moschcowitz syndrome) is an acute, life-threatening thrombotic microangiopathy (TMA) caused by severe deficiency of the von Willebrand factor-cleaving protease ADAMTS13 (activity below 10 %). Its hallmark is the triad of Coombs-negative microangiopathic hemolytic anemia with schistocytes, thrombocytopenia and ischemic organ damage, mainly affecting the brain, heart, kidneys and gut.
Classification
- Immune-mediated TTP (iTTP): more than 90 % of cases; autoantibodies against ADAMTS13 (mostly IgG) inhibit the enzyme or accelerate its clearance; typically presents in adulthood.
- Congenital TTP (cTTP, Upshaw-Schulman syndrome): about 5 % of cases, prevalence 0.5–2 per million; autosomal recessive (homozygous or compound heterozygous) mutations in the ADAMTS13 gene; onset often in infancy or childhood or first in pregnancy.
Aetiopathogenesis
ADAMTS13 cleaves ultra-large von Willebrand factor multimers released by the endothelium. If the enzyme is lacking, these multimers persist and spontaneously bind platelets. When a trigger is added (e.g. infection, pregnancy), platelet- and von Willebrand factor-rich microthrombi form at the arteriocapillary junctions of many organs. They consume platelets and shear passing red cells (mechanical, intravascular hemolysis).
The microthrombi are platelet-rich; unlike in DIC, plasmatic coagulation remains largely normal. Risk factors for iTTP are female sex and pregnancy; in US cohorts the risk was about sevenfold higher in Black people.
Clinical features
Onset may be insidious with mild complaints or acute and severe; symptoms are often non-specific.
- Thrombocytopenia (virtually always): petechiae, purpura, bruising, mucosal and retinal bleeding – often only mild
- Hemolytic anemia (virtually always): pallor, weakness, fatigue, exertional dyspnea, jaundice
- Neurological symptoms (about 61 %, severe in about 31 %), often transient and fluctuating: headache, confusion, visual disturbance, aphasia, dysarthria, hemiparesis, seizures, coma
- Kidney (about 40 %): rising creatinine, proteinuria, microscopic hematuria; acute kidney failure in only about 10 %; the kidney is more often involved in cTTP
- Gastrointestinal (about 35 %): abdominal pain, nausea, vomiting, diarrhea, pancreatitis
- Heart: troponin rise, arrhythmias, angina pectoris, myocardial infarction up to sudden cardiac death
- non-specific arthralgia, myalgia, fever
Histology
Blood smear
The key finding is schistocytes (fragmented red cells): helmet cells, triangular and bizarrely deformed red cell fragments, together with polychromasia reflecting reticulocytosis and a marked reduction in platelets. The number of schistocytes varies widely; if in doubt, the smear is reassessed the following day.
Diagnosis
- Blood count and smear: thrombocytopenia, anemia, schistocytes
- Signs of hemolysis: LDH and indirect bilirubin raised, haptoglobin low to undetectable, reticulocytes raised
- Direct Coombs test usually negative
- Coagulation (prothrombin time/INR, aPTT, fibrinogen, D-dimer) largely normal – distinction from DIC
- Organ assessment: creatinine, urinalysis, troponin, NT-proBNP, liver tests, lipase; brain imaging with neurological signs
- ADAMTS13 activity (key finding; below 10 % confirms TTP) and anti-ADAMTS13 antibodies; only citrate blood drawn before any blood products are given is informative, as EDTA inhibits the enzyme
- Genetics with absent antibodies, onset in childhood or pregnancy, relapses or a positive family history
PLASMIC score
In confirmed microangiopathic hemolysis with thrombocytopenia, it estimates the probability of severe ADAMTS13 deficiency while the result is pending. 1 point each:
- platelets below 30 G/l
- hemolysis: reticulocytes above 2.5 % or indirect bilirubin above 2 mg/dl or undetectable haptoglobin
- no active cancer
- not a transplant recipient
- MCV below 90 fl
- INR below 1.5
- creatinine below 2 mg/dl
0–4 points: low (0–4 %), 5 points: intermediate (5–24 %), 6–7 points: high probability (62–82 %).
Treatment principles
- Acquired TTP is a haematological emergency: plasma exchange is started without delay as soon as the suspicion is well founded.
- Treatment is supplemented with glucocorticoids, a nanobody directed against von Willebrand factor and anti-CD20 antibodies to suppress autoantibody production.
- Platelet transfusions are avoided unless there is life-threatening bleeding; the congenital form is treated by replacing the missing enzyme.
Specific treatment regimens with drugs and doses are covered in the InnereFuchs app.
Keep learning in the app
Further reading (open access)
Cross-references
More topics: Haematology & oncology
- Anemia (classification and work-up)
- Hemolytic anemias
- Acute myeloid leukemia (AML)
- Iron deficiency anemia
- Tumor lysis syndrome
- Vitamin B12 deficiency and pernicious anemia
- Von Willebrand disease
- Acute lymphoblastic leukemia (ALL)
- Anemia of chronic disease (anemia of inflammation)
- Antiphospholipid syndrome
- Aplastic anemia
- Autoimmune hemolytic anemia (AIHA)
Keep learning
Keep learning with flashcards, exam questions and spot diagnoses in the InnereFuchs app – free, in your browser or as an app.
Related pages: Anemia (classification and work-up) · Hemolytic anemias · Acute myeloid leukemia (AML)
Note: Learning content for medical education – not a treatment recommendation and no substitute for diagnosis or treatment decisions in individual cases. Treatment and management are deliberately not covered on this page.